EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Antithrombotic strategy according to age in patients with atrial fibrillation and drug-eluting stents: a post hoc analysis of the ADAPT AF-DES randomised trial

Sang-Hyup Lee, Soo-Jin Kim, Ae-Young Her, Byung-Ryul Cho, Gwang-Sil Kim, Taek-Geun Kwon, Sang-Wook Lim, Jaemin Shim iD, Ji-Yong Jang iD, Yong-Joon Lee iD, Seung-Jun Lee, Hee Tae Yu iD und 10 weitere

Age and Ageing · 03.08.2026 · 55 (8)

DOI: 10.1093/ageing/afag224 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Age and Ageing, online erschienen am 03.08.2026. Verfasst von Sang-Hyup Lee und 21 weiteren Autor:innen. Beteiligte Einrichtung: Yonsei University College of Medicine, Division of Cardiology, Seodaemun-gu, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Atrial Fibrillation, Drug-Eluting Stents, Percutaneous Coronary Intervention, Clopidogrel. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: Cardiovascular Research Center, National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Evidence for non-vitamin K antagonist oral anticoagulant (NOAC) monotherapy for older patients with atrial fibrillation (AF) and drug-eluting stents is lacking.

Objectives

We aimed to evaluate the safety and efficacy of NOAC monotherapy in older AF patients with drug-eluting stents.

Methods

This is a secondary analysis of the ADAPT AF-DES randomised trial comparing NOAC monotherapy with combination therapy with NOAC plus clopidogrel in patients with AF and drug-eluting stents. Patients were stratified by age (≥75 years and <75 years). Apixaban or rivaroxaban was used as the NOAC. The primary endpoint was a net adverse clinical event at 1 year after randomisation, defined as a composite of all-cause death, myocardial infarction, stent thrombosis, stroke, systemic embolism or major or clinically relevant non-major bleeding defined by the International Society on Thrombosis and Haemostasis criteria.

Results

Among 960 patients included in the ADAPT AF-DES trial, 376 (39.2%) patients were aged ≥75 years. In patients aged ≥75 years, the incidence of the primary endpoint was lower in the NOAC monotherapy group (9.8% vs. 22.3%; adjusted hazard ratio, 0.37; 95% confidence interval, 0.21–0.66; P < .001) than in the combination therapy group. In contrast, the incidences did not differ between treatment strategies in patients aged <75 years. The interaction between age groups and strategy groups did not reach statistical significance (P for interaction = .095). The reduction in major or clinically relevant non-major bleeding with NOAC monotherapy was consistent across age groups. In contrast, the benefit of NOAC monotherapy in major adverse cardiac and cerebrovascular events was more pronounced in patients aged ≥75 years, with a statistically significant interaction.

Conclusions

In this post hoc analysis, NOAC monotherapy was associated with a lower risk of net adverse clinical events, specifically within the older age subgroup. Tailored approach regarding age and individual ischaemic risk may be needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationDrug-Eluting StentsPercutaneous Coronary InterventionClopidogrelPlatelet Aggregation InhibitorsPyridonesRivaroxabanFibrinolytic AgentsAnticoagulantsCoronary Artery DiseaseHumansAgedFemaleMaleAge FactorsTreatment OutcomeDrug Therapy, CombinationRisk FactorsHemorrhagePyrazolesTime FactorsAdministration, OralMiddle AgedAged, 80 and overFactor Xa Inhibitors

Stichwörter der Autor:innen

drug-eluting stentnon-vitamin K antagonist oral anticoagulantolder patientsolder people

Substanzen

ClopidogrelapixabanPlatelet Aggregation InhibitorsPyridonesPyrazolesRivaroxabanFibrinolytic AgentsAnticoagulantsFactor Xa Inhibitors

Autor:innen und Institutionen

  • Yonsei University College of Medicine, Division of Cardiology, Seodaemun-gu, Seoul, Republic of Korea.
  • Kosin University Gospel Hospital, Division of Cardiology, Busan, Republic of Korea.
  • Kangwon National University Hospital, Division of Cardiology, Chuncheon-si, Gangwon-do, Republic of Korea.
  • Inje University Sanggye Paik Hospital, Division of Cardiology, Seoul, Nowon-gu, Republic of Korea.
  • Chungbuk National University Hospital, Division of Cardiology, Cheongju-si, Chungcheongbuk-do, Republic of Korea.
  • CHA University Bundang Medical Center, Division of Cardiology, Seongnam-si, Gyeonggi-do, Republic of Korea.

ORCID-Profile: Jaemin Shim, Ji-Yong Jang, Yong-Joon Lee, Hee Tae Yu, Byeong-Keuk Kim, Young-Guk Ko, Myeong-Ki Hong, Hui-Nam Pak, Jung-Sun Kim

Förderung

  • Cardiovascular Research Center, National Research Foundation of Korea

Zitieren

APA

Lee, S. H., Kim, S. J., Her, A. Y., Cho, B. R., Kim, G. S., Kwon, T. G., Lim, S. W., Shim, J., Jang, J. Y., Lee, Y. J., Lee, S. J., Yu, H. T., Hong, S. J., Ahn, C. M., Kim, B. K., Ko, Y. G., Choi, D., Hong, M. K., Jang, Y., …, & Heo, J. H. (2026). Antithrombotic strategy according to age in patients with atrial fibrillation and drug-eluting stents: a post hoc analysis of the ADAPT AF-DES randomised trial. Age and Ageing, 55(8). https://doi.org/10.1093/ageing/afag224

Vancouver

Lee SH, Kim SJ, Her AY, Cho BR, Kim GS, Kwon TG, et al. Antithrombotic strategy according to age in patients with atrial fibrillation and drug-eluting stents: a post hoc analysis of the ADAPT AF-DES randomised trial. Age and Ageing. 2026;55(8). doi:10.1093/ageing/afag224

BibTeX
@article{Lee2026,
  author = {Lee, Sang-Hyup and Kim, Soo-Jin and Her, Ae-Young and Cho, Byung-Ryul and Kim, Gwang-Sil and Kwon, Taek-Geun and Lim, Sang-Wook and Shim, Jaemin and Jang, Ji-Yong and Lee, Yong-Joon and Lee, Seung-Jun and Yu, Hee Tae and Hong, Sung-Jin and Ahn, Chul-Min and Kim, Byeong-Keuk and Ko, Young-Guk and Choi, Donghoon and Hong, Myeong-Ki and Jang, Yangsoo and Pak, Hui-Nam and Kim, Jung-Sun and Heo, Jung Ho},
  title = {Antithrombotic strategy according to age in patients with atrial fibrillation and drug-eluting stents: a post hoc analysis of the ADAPT AF-DES randomised trial},
  journal = {Age and Ageing},
  year = {2026},
  volume = {55},
  number = {8},
  doi = {10.1093/ageing/afag224}
}
Kostenlos starten →